The Development of New, Non-steroidal Anti-Asthma Drugs with Novel Modes of Action

哮喘是澳大利亚最重要的慢性疾病之一。它对数十万公民的生活产生不利影响，是一个日益严重的问题，特别是在人口中的年轻人中。初创生物技术公司Cryptopharma最近确定了一系列类固醇衍生物，通过一种新的作用模式，在体内模型中具有显著的抗哮喘活性。本工作的目的是通过全面的合成有机化学和药物化学类型研究，开发可用于临床治疗哮喘的Cryptopharma先导化合物的非甾体类似物。

Asthma represents one of Australia's most significant chronic disease states. It adversely affects the lives of many hundreds of thousands of citizens and represents a growing problem, especially amongst younger members of the population. The start-up biotech company Cryptopharma has recently identified a family of steroid derivatives that deliver, through a novel mode of action, significant anti-asthma activity in in-vivo models. The purpose of the present work is to develop, through comprehensive synthetic organic chemistry and medicinal chemistry-type studies, non-steroidal analogues of Cryptopharma's lead compound that can be used clinically in the treatment of asthma.